Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 125

1.

Interferon-β produces synergistic combinatory anti-tumor effects with cisplatin or pemetrexed on mesothelioma cells.

Li Q, Kawamura K, Yang S, Okamoto S, Kobayashi H, Tada Y, Sekine I, Takiguchi Y, Shingyouji M, Tatsumi K, Shimada H, Hiroshima K, Tagawa M.

PLoS One. 2013 Aug 16;8(8):e72709. doi: 10.1371/journal.pone.0072709. eCollection 2013.

2.

Upregulated p53 expression activates apoptotic pathways in wild-type p53-bearing mesothelioma and enhances cytotoxicity of cisplatin and pemetrexed.

Li Q, Kawamura K, Yamanaka M, Okamoto S, Yang S, Yamauchi S, Fukamachi T, Kobayashi H, Tada Y, Takiguchi Y, Tatsumi K, Shimada H, Hiroshima K, Tagawa M.

Cancer Gene Ther. 2012 Mar;19(3):218-28. doi: 10.1038/cgt.2011.86. Epub 2012 Jan 6.

PMID:
22223137
3.

Valproate, in combination with pemetrexed and cisplatin, provides additional efficacy to the treatment of malignant mesothelioma.

Vandermeers F, Hubert P, Delvenne P, Mascaux C, Grigoriu B, Burny A, Scherpereel A, Willems L.

Clin Cancer Res. 2009 Apr 15;15(8):2818-28. doi: 10.1158/1078-0432.CCR-08-1579. Epub 2009 Apr 7.

4.

Zoledronic acid produces combinatory anti-tumor effects with cisplatin on mesothelioma by increasing p53 expression levels.

Okamoto S, Jiang Y, Kawamura K, Shingyoji M, Fukamachi T, Tada Y, Takiguchi Y, Tatsumi K, Shimada H, Hiroshima K, Kobayashi H, Tagawa M.

PLoS One. 2013;8(3):e60297. doi: 10.1371/journal.pone.0060297. Epub 2013 Mar 28.

5.

Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma.

Gordon GJ, Mani M, Maulik G, Mukhopadhyay L, Yeap BY, Kindler HL, Salgia R, Sugarbaker DJ, Bueno R.

Cancer Chemother Pharmacol. 2008 Apr;61(4):549-58. Epub 2007 May 24.

PMID:
17522864
6.

Interferon-lambda induces G1 phase arrest or apoptosis in oesophageal carcinoma cells and produces anti-tumour effects in combination with anti-cancer agents.

Li Q, Kawamura K, Ma G, Iwata F, Numasaki M, Suzuki N, Shimada H, Tagawa M.

Eur J Cancer. 2010 Jan;46(1):180-90. doi: 10.1016/j.ejca.2009.10.002.

PMID:
19879751
7.

Intraoperative hyperthermic chemotherapy perfusion for malignant pleural mesothelioma: an in vitro evaluation.

Cameron RB, Hou D.

J Thorac Cardiovasc Surg. 2013 Feb;145(2):496-504. doi: 10.1016/j.jtcvs.2012.10.042. Epub 2012 Nov 20.

8.

Recombinant erythropoietin differently affects proliferation of mesothelioma cells but not sensitivity to cisplatin and pemetrexed.

Palumbo C, Battisti S, Carbone D, Albonici L, Alimandi M, Bei R, Modesti A.

Cancer Chemother Pharmacol. 2008 Apr;61(5):893-901. Epub 2007 Oct 6.

PMID:
17922127
9.

E1B-55 kDa-defective adenoviruses activate p53 in mesothelioma and enhance cytotoxicity of anticancer agents.

Yamanaka M, Tada Y, Kawamura K, Li Q, Okamoto S, Chai K, Yokoi S, Liang M, Fukamachi T, Kobayashi H, Yamaguchi N, Kitamura A, Shimada H, Hiroshima K, Takiguchi Y, Tatsumi K, Tagawa M.

J Thorac Oncol. 2012 Dec;7(12):1850-7. doi: 10.1097/JTO.0b013e3182725fa4.

10.

Synergistic antitumor effects of regulatory T cell blockade combined with pemetrexed in murine malignant mesothelioma.

Anraku M, Tagawa T, Wu L, Yun Z, Keshavjee S, Zhang L, Johnston MR, de Perrot M.

J Immunol. 2010 Jul 15;185(2):956-66. doi: 10.4049/jimmunol.0900437. Epub 2010 Jun 14.

11.

Preclinical emergence of vandetanib as a potent antitumour agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatin.

Giovannetti E, Zucali PA, Assaraf YG, Leon LG, Smid K, Alecci C, Giancola F, Destro A, Gianoncelli L, Lorenzi E, Roncalli M, Santoro A, Peters GJ.

Br J Cancer. 2011 Nov 8;105(10):1542-53. doi: 10.1038/bjc.2011.400. Epub 2011 Oct 4.

12.

Interaction and cross-resistance of cisplatin and pemetrexed in malignant pleural mesothelioma cell lines.

Kitazono-Saitoh M, Takiguchi Y, Kitazono S, Ashinuma H, Kitamura A, Tada Y, Kurosu K, Sakaida E, Sekine I, Tanabe N, Tagawa M, Tatsumi K.

Oncol Rep. 2012 Jul;28(1):33-40. doi: 10.3892/or.2012.1799. Epub 2012 May 4.

PMID:
22562354
13.

In vitro and in vivo therapeutic efficacy of the PPAR-γ agonist troglitazone in combination with cisplatin against malignant pleural mesothelioma cell growth.

Hamaguchi N, Hamada H, Miyoshi S, Irifune K, Ito R, Miyazaki T, Higaki J.

Cancer Sci. 2010 Sep;101(9):1955-64. doi: 10.1111/j.1349-7006.2010.01632.x.

14.

SOCS-1 gene delivery cooperates with cisplatin plus pemetrexed to exhibit preclinical antitumor activity against malignant pleural mesothelioma.

Iwahori K, Serada S, Fujimoto M, Ripley B, Nomura S, Mizuguchi H, Shimada K, Takahashi T, Kawase I, Kishimoto T, Naka T.

Int J Cancer. 2013 Jan 15;132(2):459-71. doi: 10.1002/ijc.27611. Epub 2012 May 17.

15.

The PPAR-γ agonist troglitazone antagonizes survival pathways induced by STAT-3 in recombinant interferon-β treated pancreatic cancer cells.

Vitale G, Zappavigna S, Marra M, Dicitore A, Meschini S, Condello M, Arancia G, Castiglioni S, Maroni P, Bendinelli P, Piccoletti R, van Koetsveld PM, Cavagnini F, Budillon A, Abbruzzese A, Hofland LJ, Caraglia M.

Biotechnol Adv. 2012 Jan-Feb;30(1):169-84. doi: 10.1016/j.biotechadv.2011.08.001. Epub 2011 Aug 17.

PMID:
21871555
16.

Agonist activation of estrogen receptor beta (ERβ) sensitizes malignant pleural mesothelioma cells to cisplatin cytotoxicity.

Pinton G, Manente AG, Daga A, Cilli M, Rinaldi M, Nilsson S, Moro L.

Mol Cancer. 2014 Oct 2;13:227. doi: 10.1186/1476-4598-13-227.

17.

Pemetrexed: new drug. Pleural mesothelioma: a first encouraging trial.

[No authors listed]

Prescrire Int. 2005 Dec;14(80):212-4.

PMID:
16400741
18.

Standard therapy for the treatment of malignant pleural mesothelioma.

Vogelzang NJ.

Lung Cancer. 2005 Oct;50 Suppl 1:S23-4.

PMID:
16291429
19.

A comparison of the antitumor effects of interferon-alpha and beta on human hepatocellular carcinoma cell lines.

Murata M, Nabeshima S, Kikuchi K, Yamaji K, Furusyo N, Hayashi J.

Cytokine. 2006 Feb 7;33(3):121-8. Epub 2006 Mar 7.

PMID:
16522372
20.

FDA drug approval summaries: pemetrexed (Alimta).

Hazarika M, White RM, Johnson JR, Pazdur R.

Oncologist. 2004;9(5):482-8. Review.

Supplemental Content

Support Center